Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Proteins | 9 | 2024 | 222 | 2.840 |
Why?
|
| Antioxidants | 6 | 2025 | 439 | 2.490 |
Why?
|
| Mitochondria | 5 | 2024 | 516 | 1.230 |
Why?
|
| Calcium | 3 | 2017 | 487 | 0.900 |
Why?
|
| Potentiometry | 2 | 2023 | 8 | 0.860 |
Why?
|
| Triazoles | 2 | 2021 | 100 | 0.770 |
Why?
|
| Pleural Neoplasms | 4 | 2009 | 57 | 0.740 |
Why?
|
| Mesothelioma | 5 | 2009 | 148 | 0.730 |
Why?
|
| Inflammation | 4 | 2024 | 729 | 0.710 |
Why?
|
| Homeostasis | 5 | 2022 | 193 | 0.700 |
Why?
|
| Imidazoles | 1 | 2021 | 138 | 0.690 |
Why?
|
| Phenols | 1 | 2021 | 102 | 0.670 |
Why?
|
| Drug Design | 1 | 2021 | 183 | 0.650 |
Why?
|
| Calcium Signaling | 3 | 2017 | 108 | 0.630 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 479 | 0.630 |
Why?
|
| Aging | 4 | 2024 | 764 | 0.580 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 518 | 0.560 |
Why?
|
| Ear, Inner | 1 | 2017 | 2 | 0.530 |
Why?
|
| Aging, Premature | 1 | 2017 | 6 | 0.530 |
Why?
|
| Hearing Loss | 1 | 2017 | 16 | 0.530 |
Why?
|
| Energy Metabolism | 1 | 2017 | 181 | 0.480 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2024 | 188 | 0.460 |
Why?
|
| Autoimmunity | 1 | 2015 | 56 | 0.460 |
Why?
|
| Carnitine O-Palmitoyltransferase | 2 | 2024 | 10 | 0.430 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 7 | 0.430 |
Why?
|
| NF-kappa B | 2 | 2014 | 355 | 0.430 |
Why?
|
| Acinetobacter Infections | 1 | 2013 | 24 | 0.410 |
Why?
|
| Mice | 12 | 2024 | 6490 | 0.410 |
Why?
|
| Acinetobacter baumannii | 1 | 2013 | 35 | 0.400 |
Why?
|
| Neutrophils | 1 | 2013 | 141 | 0.390 |
Why?
|
| Peritonitis | 1 | 2012 | 11 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 276 | 0.370 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2009 | 78 | 0.360 |
Why?
|
| Oxidation-Reduction | 3 | 2021 | 448 | 0.340 |
Why?
|
| Animals | 15 | 2024 | 16695 | 0.320 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2020 | 34 | 0.310 |
Why?
|
| Macrophages | 1 | 2013 | 515 | 0.310 |
Why?
|
| Mice, Knockout | 4 | 2024 | 1010 | 0.300 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 683 | 0.300 |
Why?
|
| Proteoglycans | 1 | 2009 | 49 | 0.300 |
Why?
|
| Antiviral Agents | 2 | 2021 | 189 | 0.300 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 599 | 0.270 |
Why?
|
| Neoplasms | 2 | 2015 | 1341 | 0.250 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2006 | 13 | 0.240 |
Why?
|
| Schizosaccharomyces | 1 | 2006 | 16 | 0.240 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2025 | 5 | 0.240 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2006 | 71 | 0.240 |
Why?
|
| Coordination Complexes | 1 | 2025 | 28 | 0.230 |
Why?
|
| Methyltransferases | 1 | 2006 | 66 | 0.230 |
Why?
|
| Gene Silencing | 1 | 2006 | 154 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2024 | 31 | 0.220 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 99 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 239 | 0.210 |
Why?
|
| Electrons | 2 | 2021 | 74 | 0.210 |
Why?
|
| Electrodes | 1 | 2023 | 57 | 0.210 |
Why?
|
| Iron | 1 | 2025 | 247 | 0.200 |
Why?
|
| Oxidative Stress | 2 | 2021 | 990 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 297 | 0.200 |
Why?
|
| Cyclin D1 | 1 | 2022 | 44 | 0.190 |
Why?
|
| Picrates | 1 | 2021 | 7 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 130 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 52 | 0.180 |
Why?
|
| Kidney | 1 | 2024 | 363 | 0.180 |
Why?
|
| Cell Cycle | 2 | 2022 | 348 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 2598 | 0.170 |
Why?
|
| Amino Acid Sequence | 3 | 2014 | 1188 | 0.170 |
Why?
|
| Asbestos | 2 | 2012 | 57 | 0.170 |
Why?
|
| Electrochemical Techniques | 1 | 2020 | 30 | 0.170 |
Why?
|
| Chelating Agents | 1 | 2020 | 53 | 0.160 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 1559 | 0.160 |
Why?
|
| Molybdenum | 1 | 2020 | 18 | 0.160 |
Why?
|
| Tungsten Compounds | 1 | 2020 | 16 | 0.160 |
Why?
|
| Half-Life | 1 | 2020 | 63 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 75 | 0.160 |
Why?
|
| Molecular Structure | 1 | 2021 | 560 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2020 | 2111 | 0.150 |
Why?
|
| Tissue Fixation | 1 | 2019 | 18 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2012 | 452 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 94 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1112 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 427 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 1804 | 0.140 |
Why?
|
| Mitochondrial Proteins | 2 | 2024 | 112 | 0.140 |
Why?
|
| Flow Cytometry | 1 | 2019 | 411 | 0.140 |
Why?
|
| Sperm Count | 1 | 2017 | 28 | 0.130 |
Why?
|
| Spiral Ganglion | 1 | 2017 | 6 | 0.130 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2017 | 10 | 0.130 |
Why?
|
| Sperm Motility | 1 | 2017 | 45 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 43 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 54 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 59 | 0.130 |
Why?
|
| Acetylcysteine | 1 | 2017 | 57 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 160 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1420 | 0.120 |
Why?
|
| Mutation | 2 | 2015 | 1169 | 0.120 |
Why?
|
| Antibodies, Viral | 2 | 2011 | 295 | 0.120 |
Why?
|
| Humans | 13 | 2024 | 42163 | 0.120 |
Why?
|
| Adiposity | 1 | 2017 | 155 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2019 | 426 | 0.120 |
Why?
|
| Glycolysis | 1 | 2015 | 71 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1554 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 205 | 0.110 |
Why?
|
| Epitope Mapping | 2 | 2011 | 31 | 0.110 |
Why?
|
| Kidney Tubules | 2 | 2024 | 38 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 310 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 54 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 24 | 0.100 |
Why?
|
| Male | 7 | 2024 | 22779 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2013 | 53 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 89 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 86 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 244 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 933 | 0.100 |
Why?
|
| Ion Channels | 1 | 2012 | 74 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 91 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 149 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2011 | 73 | 0.090 |
Why?
|
| Epitopes | 1 | 2011 | 155 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 649 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 118 | 0.090 |
Why?
|
| Viral Envelope Proteins | 1 | 2011 | 90 | 0.090 |
Why?
|
| Lung | 1 | 2013 | 484 | 0.080 |
Why?
|
| Protein Binding | 1 | 2014 | 1076 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 928 | 0.080 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 1617 | 0.080 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 63 | 0.080 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2009 | 1 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 271 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2009 | 36 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2009 | 168 | 0.080 |
Why?
|
| Osteopontin | 1 | 2009 | 45 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1066 | 0.070 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 661 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 19 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 25 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 129 | 0.070 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2008 | 7 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1265 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 165 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 150 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 658 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 214 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 221 | 0.060 |
Why?
|
| Protein Methyltransferases | 1 | 2006 | 6 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 711 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2006 | 29 | 0.060 |
Why?
|
| Electrophoresis | 1 | 2006 | 24 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1058 | 0.060 |
Why?
|
| Deoxyribonucleases | 1 | 2006 | 27 | 0.060 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2006 | 30 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2006 | 149 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2006 | 195 | 0.060 |
Why?
|
| Cell Movement | 1 | 2009 | 640 | 0.060 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2024 | 141 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 454 | 0.050 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 5 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2024 | 77 | 0.050 |
Why?
|
| West Nile virus | 1 | 2005 | 74 | 0.050 |
Why?
|
| Phosphates | 1 | 2023 | 54 | 0.050 |
Why?
|
| RNA | 1 | 2006 | 266 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2024 | 168 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 301 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2024 | 134 | 0.050 |
Why?
|
| Russia | 2 | 2017 | 28 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Astrocytes | 1 | 2024 | 244 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 61 | 0.050 |
Why?
|
| Electricity | 1 | 2021 | 12 | 0.050 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2021 | 41 | 0.050 |
Why?
|
| Electrochemistry | 1 | 2021 | 38 | 0.040 |
Why?
|
| Hippocampus | 1 | 2024 | 591 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2024 | 548 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 421 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 184 | 0.040 |
Why?
|
| Aristolochic Acids | 1 | 2019 | 1 | 0.040 |
Why?
|
| Polyploidy | 1 | 2019 | 8 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2019 | 65 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 2011 | 55 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 148 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2017 | 7 | 0.030 |
Why?
|
| Economics | 1 | 2017 | 7 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 875 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 25 | 0.030 |
Why?
|
| Aged | 3 | 2022 | 7982 | 0.030 |
Why?
|
| Stents | 1 | 2017 | 66 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1452 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 206 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 534 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 242 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 2011 | 21 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 2803 | 0.020 |
Why?
|
| Female | 3 | 2024 | 24018 | 0.020 |
Why?
|
| Pleura | 1 | 2009 | 5 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 75 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 92 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 139 | 0.020 |
Why?
|
| Asbestosis | 1 | 2008 | 7 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 48 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 157 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 77 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 237 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 362 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 366 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 574 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 661 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 602 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 534 | 0.010 |
Why?
|
| Hybridomas | 1 | 2005 | 24 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 850 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 50 | 0.010 |
Why?
|
| Vero Cells | 1 | 2005 | 109 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2005 | 86 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 845 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1266 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 11819 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 884 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 2485 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 979 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 13458 | 0.010 |
Why?
|